Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796670 | 0.96 | HDAC1 (0.77) | HDAC1CYP19A1L3MBTL1 | |
| SCHEMBL15795600 | 0.94 | HDAC1 (0.75) | HDAC1CYP19A1L3MBTL1 | |
| SCHEMBL1311300 | 0.91 | HDAC1 (0.66) | HDAC1CYP19A1HRH4HSP90AB1 | |
| SCHEMBL15796419 | 0.90 | HDAC1 (0.69) | HDAC1CYP19A1L3MBTL1 | |
| SCHEMBL15796735 | 0.89 | HDAC1 (0.58) | HDAC1CYP19A1L3MBTL1HRH4HSP90AB1 | |
| SCHEMBL16744515 | 0.88 | HDAC1 (0.57) | HDAC1CYP19A1L3MBTL1HSP90AB1 | |
| SCHEMBL15796818 | 0.87 | HDAC1 (0.56) | HDAC1CYP19A1L3MBTL1HRH4 | |
| SCHEMBL16206208 | 0.86 | CYP19A1 (0.82) | HDAC1CYP19A1HRH4HSP90AB1 | |
| SCHEMBL2194279 | 0.86 | CYP19A1 (0.77) | HDAC1CYP19A1HRH4HSP90AB1 | |
| SCHEMBL20969108 | 0.85 | HDAC1 (0.62) | HDAC1CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-9763957-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20170007614-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-01-12 | — | — | US | disclosed |
| US-9409895-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| EP-3022202-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| CN-105555783-A | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| CN-104968656-A | AUTOTAXIN INHIBITORS | NOVARTIS AG | 2015-10-07 | — | — | CN | disclosed |
| WO-2015008230-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-20140171403-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20080299046-A1 | METHODS FOR CONTROLLING SURFACE FUNCTIONALITY OF METAL OXIDE NANOPARTICLES, METAL OXIDE NANOPARTICLES HAVING CONTROLLED FUNCTIONALITY, AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | HDAC1 2666/4885CYP19A1 3993/4885L3MBTL1 3262/4885 |
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | HDAC1 1497/4885CYP19A1 3901/4885L3MBTL1 3543/4885 |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | HDAC1 2666/4885CYP19A1 3993/4885L3MBTL1 3262/4885 |
| US-20140171403-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | HDAC1 2666/4885CYP19A1 3993/4885L3MBTL1 3262/4885 |
| US-20170007614-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | HDAC1 2666/4885CYP19A1 3993/4885L3MBTL1 3262/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | HDAC1 2666/4885CYP19A1 3993/4885L3MBTL1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.